AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric welcomes Dr Stephanie H. Astrow as Vice President of Translational Sciences.
- Dr Astrow has over two decades of experience in the fields of biotechnology and cell therapy.
- She has extensive expertise in autologous as well as allogenic settings.
Chimeric Therapeutics (ASX:CHM) has beefed up its team with a new addition. The Australian leader in cell therapy has appointed Dr Stephanie H. Astrow as Vice President of Translational Sciences.
Following the news, shares of Chimeric were shining on Thursday at AU$0.105 with a gain of nearly 5%.
Dr Astrow brings in extensive expertise in cell therapy and biotechnology, having worked for more than two decades. An inventor on number of patents, Dr Astrow has also published papers in various fields including diagnostics development and oncology therapy.
Let us look at the previous career highlights of Dr Astrow
Image source: © 2022 Kalkine Media®, data source: CHM update
Further, Dr Astrow has participated in the approvals of several clinical assays including molecular and companion diagnostics that are deployed in selecting cancer therapies.
Educational Qualification
- Bachelor of Arts in Biology and Medicine - Brown University
- PhD in Molecular and Cell Biology - University of California, Berkeley
- Master of Business Administration - Pepperdine University
Words by the management team
Commenting on her appointment, Chimeric’s Chief Medical Officer Dr Jason B. Litten, said, “This is a critical role on our team, and Dr Astrow is a great scientist with deep cell therapy experience.”
Industry leader Dr Jason B. Litten recently joined the company as its CMO. Dr Litten is enriched with about 15 years of experience in drug development.
Image source: © 2022 Kalkine Media®
